


## **Supplementary Information**

Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma.

**Sami Mamand, Rebecca L. Allchin, Matthew J. Ahearne and Simon D. Wagner**

### **Supplemental Figure 1**

RLK protein expression in K299. Western blots probed with anti-RLK (left-hand panel) and simultaneously with anti-phospho-tyrosine and anti-GAPDH (right-hand panels). Molecular weight is indicated to the left of each blot. The expected molecular weight of RLK is ~61 kDa as indicated by the blue arrowheads.




Mamand et al.  
Supp. Fig 1

## **Transparency Information**


# Figure 2A

Jurkat and K299 cell lines




# Figure 2A

MOLT-4 and CCRF cell lines




# Figure 2B

Jurkat and K299 cell lines




# Figure 2B

MOLT-4 and CCRF cell lines




# Figure 2B

Jurkat and K299 cell lines




# Figure 2B

MOLT-4 and CCRF cell lines




# Figure 3A

ITK-siRNA Knockdown








# Figure 5E








# Figure 4A

AKT, MEK1/2 and PLCy1




- 1. Unstimulated
- 2. DMSO
- 3. PF-06465469
- 4. Ibrutinib
- 5. ONO00779050
- 6. BMS509744
- 7. Ramos
- 8. HEK293



## Figure 4B

Cytoplasmic-NFATc1




1. Untreated
2. DMSO
3. Ibrutinib
4. ONO00779050
5. DMSO
6. Ibrutinib
7. ONO00779050

---

## Figure 4B

Nuclear-NFAT



1. Untreated
2. DMSO
3. Ibrutinib
4. ONO00779050
5. DMSO
6. Ibrutinib
7. ONO00779050